Oncology Measuring Biomarkers at Every Stage of Tumor Development The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research. Simoa® assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions. REQUEST MORE INFORMATION Click through the alphabet to see available assays A B C E F G H I K L M N O P R S T V ANG-1 ANG-2 ANGIOGENESIS FACTOR PANEL 1 (ANG-2, FGFB, HB-EGF, HGF, PLGF, VEGF, VEGF-C) Related Publications SEP 20, 2021 Anesthesia triggers drug delivery to experimental glioma in mice by hijacking caveolar transport READ ARTICLE SEP 11, 2021 Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas READ ARTICLE SEP 8, 2021 Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models READ ARTICLE SEE ALL RELATED PUBLICATIONS Stay Tuned Subscribe to our newsletter SUBMIT info@quanterix.com 617 301 9400 900 middlesex tpke billerica, ma 01821 usa Investor Portal Customer Portal Contact Us Terms And Conditions Privacy Shield Statement © 2021 Quanterix All rights reserved. Privacy Policy By continuing to use this website you are acknowledging and agree with our cookie policy. AGREELearn more